argus

Gland Pharma Limited

NSE: GLANDINE068V0102347,834 Cr

Timeline

Time (IST)TypeMEventSrc
15 May, 04:46 pmGland Pharma Ltd - 543245 - Corporate Action-Board approves Dividendbse
15 May, 04:42 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
15 May, 04:38 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
15 May, 04:35 pmGland Pharma Limited has informed the Exchange about Investor Presentationnse
15 May, 04:32 pmGland Pharma Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Q4FY26 Audited Financial results".nse
15 May, 04:25 pmGland Pharma Ltd - 543245 - Q4FY26 Audited Financial Resultsbse
15 May, 04:20 pmGland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of Board Meeting - 15052026bse
15 May, 04:20 pmGland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.nse
14 May, 06:33 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
14 May, 06:32 pmGland Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.nse
12 May, 05:20 pmGland Pharma Limited has informed the Exchange regarding 'Intimation of ESOP Compensation Committee Meeting'.nse
30 Apr, 01:09 pmGland Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.nse
27 Apr, 02:26 pmGland Pharma Limited has informed the Exchange regarding 'Clarification with respect to Announcement made on 13th April , 2026, regarding Postal Ballot Notice'.nse
21 Apr, 05:06 pmGland Pharma Ltd - 543245 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026 And To Consider And Recommend Payment Of Final Dividend, If Any For The Financial Year Ended March 31, 2026bse
09 Apr, 07:12 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Directoratebse
09 Apr, 07:08 pmGland Pharma Ltd - 543245 - Board Meeting Outcome for Reappointment Of Ms. Naina Lal Kidwai As An Independent Director, Subject To Shareholders Approvalbse
09 Apr, 07:07 pmGland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 09, 2026.nse
06 Apr, 12:15 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Managementbse
06 Apr, 12:14 pmGland Pharma Limited has informed the Exchange regarding Appointment of Mr Prasadha rao Lysetti as Other of the company w.e.f. April 06, 2026.nse
06 Mar, 04:01 pmGland Pharma Ltd - 543245 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015bse
06 Mar, 04:01 pmGland Pharma Limited has informed the Exchange about Order passed by the GST Authoritynse
04 Mar, 11:06 amGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
04 Mar, 11:04 amGland Pharma Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Gland Pharma Receives Tentative Approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC)".nse
03 Mar, 07:10 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)bse
03 Mar, 07:09 pmGland Pharma Limited has informed the Exchange regarding Resignation of Mr Shyamakant Giri as Chief Executive Officer of the company w.e.f. April 30, 2026.nse
03 Mar, 06:52 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Issue of Securitiesbse
03 Mar, 06:52 pmGland Pharma Limited has informed the Exchange about Options to purchase securitiesnse
18 Feb, 12:11 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Managementbse
18 Feb, 12:06 pmGland Pharma Limited has informed the Exchange regarding Appointment of Mr Jitendra Gangwal as Other of the company w.e.f. February 18, 2026.nse
06 Feb, 11:13 amGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
06 Feb, 11:11 amGland Pharma Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Gland Pharma Receives Approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags".nse
03 Feb, 05:03 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
03 Feb, 05:02 pmGland Pharma Limited has informed the Exchange about Transcriptnse
29 Jan, 04:13 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Change in Managementbse
29 Jan, 04:12 pmGland Pharma Limited has informed the Exchange about change in Managementnse
28 Jan, 09:16 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
28 Jan, 09:15 pmGland Pharma Limited has informed the Exchange about Link of Recordingnse
28 Jan, 05:28 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
28 Jan, 05:27 pmGland Pharma Limited has informed the Exchange about Investor Presentationnse
28 Jan, 05:23 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
28 Jan, 05:23 pmGland Pharma Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "UFR Q3FY26".nse
28 Jan, 05:18 pmGland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of Board Meeting Held On January 28, 2026bse
28 Jan, 05:14 pmGland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025bse
28 Jan, 05:10 pmGland Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.nse
09 Jan, 12:24 pmGland Pharma Ltd - 543245 - Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025bse
07 Jan, 03:41 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
07 Jan, 03:40 pmGland Pharma Limited has informed the Exchange regarding a press release dated January 07, 2026, titled "Gland Pharma receives approval from the United States Food and Drug Administration (USFDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)".nse
07 Nov, 04:42 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
07 Nov, 04:41 pmGland Pharma Limited has informed the Exchange about Transcriptnse
03 Nov, 09:24 pmGland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse